Smith & Nephew's European Trufit Study

Defect of Articular Cartilage Clinical Trial

Official title:

A Prospective, Multi-Center, Randomized, Single-Blind, Controlled Study Comparing the Trufit CB (Cartilage Bone) Implant to Microfracture for the Treatment of Patients With Single, Isolated Defects of the Knee

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01246635
• Other study ID #: CSA-2005-02
• Status: Terminated
• Phase: N/A
• Start date: April 15, 2008
• Est. completion date: December 2014

Study information

• Verified date: March 2021
• Source: Smith & Nephew, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this clinical study is to demonstrate the effectiveness and safety of the Trufit CB (Cartilage Bone) implant for the treatment of single, isolated cartilage defects of the knee compared to Microfracture.

Description:

Up to 315 subjects, ages 18 years and older with a single, isolated cartilage defect of the knee will be randomized in a 1:1:1 ratio to 1 of 3 treatment groups: - Trufit CB Implant with rehabilitation protocol; - Trufit CB Implant with rehabilitation protocol; - Microfracture with rehabilitation protocol Rehabilitation program may be standard (6 weeks touch weight to full weight bearing) or accelerated (2 weeks touch weight to full weight bearing).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 153
• Est. completion date: December 2014
• Est. primary completion date: November 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Capable of providing informed consent;
• Eighteen (18) years or older and skeletally mature on the date of study enrollment;
• Willing and able to attend all follow up visits and complete all study related procedures and evaluations including, but not limited to adhering to the rehabilitation protocol;
• Single, isolated cartilage defect (ICRS Grade III - IV) in the knee (medial or lateral femoral condyle or trochlea) that is = 1cm2 (10 mm) and = 2cm2 (20 mm) in area and requiring a maximum of 2 implants (if randomized to TRUFIT CB); Note: Lesion size should be assessed as the product of the longest diameter and its perpendicular applied at the widest portion of the lesion.
• Candidate for cartilage repair surgery as a result of a single, isolated symptomatic cartilage lesion;
• Presents with stable health at the time of study enrollment;
• BMI of = 32.

Exclusion Criteria:

• Female of child-bearing potential who is pregnant or plans to become pregnant over the course of the study;
• History of alcohol or drug abuse;
• Presents with patellofemoral instability or other anatomical malalignment in the study knee;
• Any diagnosis that would preclude the patient from successfully completing the study rehabilitation protocols;
• Unable or unwilling to follow post operative procedures (e.g. rehabilitation protocol);
• Received one or more intra-articular steroid injections in the study knee within the previous 3 months;
• Presents with ipsilateral hip disease, as determined by pain or restricted range of motion upon physical examination;
• Treated with either an investigational device or drug within one (1) month of study enrollment, or plans to be treated with an investigational device or drug in the next 24 months;
• Diagnosed rheumatoid arthritis, ankylosing spondylitis (Bechterew syndrome), or calcium pyrophosphate dihydrate disease(chondrocalcinosis);
• History of severe vascular or neurological disease, uncontrolled diabetes, or is immunosuppressed (e.g. HIV positive);
• Musculoskeletal disease, including degenerative bone diseases such as osteochondritis dissecans and osteonecrosis;
• Pathologic conditions of the bone (e.g. osteoporosis, cystic changes, hyperparathyroidism, Paget's Disease, hypercalcemia, prolonged use of steroids);
• Active infection, or evidence thereof, at the lesion site;
• Requires the use of any medication(s) or treatment(s) known to have an effect on bone metabolism (e.g. bisphosphonates, chemotherapeutic or immunosuppressive agents);
• Requires concomitant osteotomy, partial lateral meniscectomy or complete meniscectomy; Note: Concomitant ACL reconstruction or revision, as well as meniscal repair and partial medial meniscectomies are permitted under the study protocol.
• Has undergone an ACL reconstruction, osteotomy, chondral resurfacing procedure or partial meniscectomy (= central third of the meniscus) in the last year and has not completed at least 6 months of rehabilitation since such surgery; Note: Patients who have undergone these procedures within the last year and have completed at least 6 months of rehabilitation are eligible to participate in the study.
• Any active, implanted medical device (e.g. cochlear implant) or metallic implant (other then dental work) that may interfere with Magnetic Resonance Imaging (MRI);
• Any condition (e.g. claustrophobia) that may interfere with the patient's ability to undergo MRI;
• Diagnosis requiring placement of an active implant (e.g. cardiac pacemaker, vagus nerve stimulator, etc.) within the next 24 months.

Related Conditions & MeSH terms

• Cartilage Diseases
• Defect of Articular Cartilage

Intervention

Device:
• Trufit CB (Cartilage Bone) Implant
Implantation of 5,7, 9, or 11 mm Trufit CB Implants for small cartilage lesions. A maximum of two Trufit CB plugs may be implanted.

Procedure:
• Microfracture if the knee
Creation of small holes through subchondral bone with the goal of stimulating cartilage growth

Locations

Country	Name	City	State
Belgium	Karl Brabants, MD	Antwerp
Belgium	Prof. Dr. K.F. Almqvist	Ghent
Belgium	Toon Claes, MD	Herentals
Belgium	Johan Vanlauwe	Leuven
Denmark	Aalborg Private Hospital A/S	Aalborg
Germany	Johannes Holz, MD	Hamburg
Ireland	Kevin J. Mulhall	Dublin
Netherlands	Sander Koeter, MD	Nijmegen
Netherlands	Kees van Egmond, MD	Zwolle
Norway	Lars Engebretsen, MD	Oslo
Sweden	Magnus Forssblad, MD	Stockholm
United Kingdom	Angus Robertson, MD	Cardiff
United Kingdom	Tim Spalding, MD	Coventry
United Kingdom	David Chesney	Fife Keith

Sponsors (1)

Lead Sponsor	Collaborator
Smith & Nephew, Inc.

Countries where clinical trial is conducted

Belgium,  Denmark,  Germany,  Ireland,  Netherlands,  Norway,  Sweden,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent change in the Knee injury and Osteoarthritis Outcome Score (KOOS) from baseline		6 months post-procedure
Secondary	Percent improvement from baseline in the KOOS Knee Survey Score at all time-points		2 weeks, 6, weeks, 3 months, (6 months - primary measure), 12 months and 24 months post-procedure
Secondary	Positive change in activity level from baseline to each visit, as measured by the Tegner Activity Scale at all time-points.		2 weeks, 6 weeks, 3 months, 6 months, 12 months and 24 months post-procedure
Secondary	Difference in Pain Scores on the Visual Analog Scale from baseline at all post operative time-points.		2 weeks, 6 weeks, 3 months, 6 months, 12 months and 24 months post-procedure
Secondary	Magnetic resonance evaluation of cartilage and underlying bone using the MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue) scale		12 and 24 months post-procedure
Secondary	Proportion of subjects (compared to baseline) with cartilage classifications within the four groups defined by the International Cartilage Repair Society (ICRS) scoring system	Evaluation of cartilage at 24 months post-procedure will only occur for subjects who consent to a second-look biopsy.	24 months post-procedure
Secondary	Histological evaluation of cartilage	Histological characterization of cartilage will only occur for those subjects consenting to both the second look arthroscopy and biopsy at 24-months post-procedure.	24 months post-procedure
Secondary	Number of Participants with Adverse Events as a Measure of Safety and Tolerability		2 weeks, 6 weeks, 3 months, 6 months, 12 months and 24 months post-procedure